Moore, Kathleen N.
Bauer, Todd M.
Falchook, Gerald S.
Chowdhury, Swapan
Patel, Chirag
Neuwirth, Rachel
Enke, Aaron
Zohren, Fabian
Patel, Manish R.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
https://doi.org/10.1136/esmoopen-2017-000291
Documents that mention this clinical trial
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
https://doi.org/10.1136/esmoopen-2017-000291
Funding for this research was provided by:
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
This article is maintained by: Elsevier
Article Title: Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
Journal Title: ESMO Open
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/esmoopen-2017-000291
Content Type: article
Copyright: © 2018 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.